摘要
常规放化疗治疗进展期头颈部鳞状细胞癌（HNSCC）的不良反应大，疗效有限。近期临床研究表明表皮生长因子受体（EGFR）抑制剂西妥昔单抗联合放疗治疗局部晚期HNSCC显示高效低毒的优越性，单药对铂类耐药病例仍有一定疗效。西妥昔单抗在HNSCC的综合治疗中有广阔的应用前景。
The therapeutic effect of conventional radiotherapy or chemotherapy in advanced head and neck squamous cell carcinoma （HNSCC） is limited with higher toxicity. Recent clinical trials confirm that epidermal growth factor receptor inhibitor cetuximab enhances the anti-tumor effect of radiotherapy in local advanced HNSCC with lower toxicity, and is active as monotherapy in patients who progressed on platinum based therapy. Cetuximab is promising in the muhidisciplinary synthetic therapy of HNSCC.
出处
《国际肿瘤学杂志》
CAS
2007年第10期751-754,共4页
Journal of International Oncology
关键词
受体
表皮生长因子
受体酪氨酸激酶
头颈部肿瘤
癌
鳞状细胞
Receptor, epidermal growth factor
Receptor tyrosine kinase
Head and neck neoplasms
Carcinoma, squamous cell
